These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17218843)

  • 1. Ambivalency at the bedside: intraperitoneal chemotherapy.
    Rodriguez AO
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):1-2. PubMed ID: 17218843
    [No Abstract]   [Full Text] [Related]  

  • 2. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
    Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC
    Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166
    [No Abstract]   [Full Text] [Related]  

  • 3. Intraperitoneal therapy for ovarian cancer: why has it not become standard?
    Rowan K
    J Natl Cancer Inst; 2009 Jun; 101(11):775-7. PubMed ID: 19470952
    [No Abstract]   [Full Text] [Related]  

  • 4. Intraperitoneal chemotherapy for ovarian cancer.
    Ozols RF; Bookman MA; Young RC
    N Engl J Med; 2006 Apr; 354(15):1641-3; author reply 1641-3. PubMed ID: 16611959
    [No Abstract]   [Full Text] [Related]  

  • 5. Feasibility of intraperitoneal chemotherapy in advanced epithelial ovarian cancer.
    Maheshwari A; Gupta S; Prabhash K; Tongaonkar HB
    Indian J Cancer; 2010; 47(2):225-6. PubMed ID: 20448394
    [No Abstract]   [Full Text] [Related]  

  • 6. Chemotherapy delivered into abdomen may extend ovarian cancer survival.
    Mayo Clin Womens Healthsource; 2006 Jun; 10(6):3. PubMed ID: 16675917
    [No Abstract]   [Full Text] [Related]  

  • 7. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
    Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
    Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraperitoneal chemotherapy comes of age.
    Cannistra SA
    N Engl J Med; 2006 Jan; 354(1):77-9. PubMed ID: 16394306
    [No Abstract]   [Full Text] [Related]  

  • 9. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study.
    Wenzel LB; Huang HQ; Armstrong DK; Walker JL; Cella D;
    J Clin Oncol; 2007 Feb; 25(4):437-43. PubMed ID: 17264340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A relevant historical perspective on the current toxicity of IP chemotherapy: implications for the future.
    Markman M
    Gynecol Oncol; 2007 Jun; 105(3):561-2. PubMed ID: 17428522
    [No Abstract]   [Full Text] [Related]  

  • 11. Intraperitoneal therapy for advanced ovarian cancer: will it become standard care?
    Bankhead C
    J Natl Cancer Inst; 2006 Apr; 98(8):510-2. PubMed ID: 16622116
    [No Abstract]   [Full Text] [Related]  

  • 12. Laparoscopic placement of PAP catheters for intraperitoneal chemotherapy in ovarian carcinoma.
    Arts HJ; Willemse PH; Tinga DJ; de Vries EG; van der Zee AG
    Gynecol Oncol; 1998 Apr; 69(1):32-5. PubMed ID: 9570995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma.
    Lin CC; Yeh KH; Yang CH; Hsu C; Tsai YC; Hsu WL; Cheng AL; Hsu CH
    Anticancer Drugs; 2007 Jul; 18(6):703-8. PubMed ID: 17762400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer.
    Onujiogu N; Lengyel E; Yamada SD
    Gynecol Oncol; 2008 Dec; 111(3):537-9. PubMed ID: 18554701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraperitoneal chemotherapy for women with advanced epithelial ovarian carcinoma.
    Trimble EL; Christian MC
    Gynecol Oncol; 2006 Jan; 100(1):3-4. PubMed ID: 16368439
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of intraperitoneal chemotherapy in ovarian cancer.
    Markman M
    Clin Adv Hematol Oncol; 2006 Nov; 4(11):809-10. PubMed ID: 17143249
    [No Abstract]   [Full Text] [Related]  

  • 17. Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care.
    Fung-Kee-Fung M; Provencher D; Rosen B; Hoskins P; Rambout L; Oliver T; Gotlieb W; Covens A;
    Gynecol Oncol; 2007 Jun; 105(3):747-56. PubMed ID: 17368522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraperitoneal chemotherapy for ovarian cancer: 2009 goals.
    Walker JL
    Gynecol Oncol; 2009 Mar; 112(3):439-40. PubMed ID: 19245944
    [No Abstract]   [Full Text] [Related]  

  • 19. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment.
    Markman M; Walker JL
    J Clin Oncol; 2006 Feb; 24(6):988-94. PubMed ID: 16461779
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma.
    Chin SN; Pinto V; Rosen B; Oza A; Dodge J; Murphy J; Mackay H
    Gynecol Oncol; 2009 Mar; 112(3):450-4. PubMed ID: 19135709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.